Comparing Daxor (NASDAQ:DXR) & LifeStance Health Group (NASDAQ:LFST)

Daxor (NASDAQ:DXR) and LifeStance Health Group (NASDAQ:LFST) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Volatility & Risk

Daxor has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Comparatively, LifeStance Health Group has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Insider & Institutional Ownership

1.3% of Daxor shares are owned by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are owned by institutional investors. 59.5% of Daxor shares are owned by insiders. Comparatively, 3.2% of LifeStance Health Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Daxor and LifeStance Health Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0	0	1	0	3.00
LifeStance Health Group	1	0	5	1	2.86

Daxor presently has a consensus target price of $25.00, indicating a potential upside of 92.90%. LifeStance Health Group has a consensus target price of $8.50, indicating a potential upside of 56.83%. Given Daxor’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Daxor is more favorable than LifeStance Health Group.

Profitability

This table compares Daxor and LifeStance Health Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
LifeStance Health Group	-1.23%	-1.11%	-0.76%

Valuation & Earnings

This table compares Daxor and LifeStance Health Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
LifeStance Health Group	$1.32 billion	1.60	-$57.44 million	($0.05)	-108.40

Daxor has higher earnings, but lower revenue than LifeStance Health Group.

Summary

Daxor beats LifeStance Health Group on 6 of the 11 factors compared between the two stocks.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

About LifeStance Health Group

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.